These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22876809)

  • 1. Targeted breast cancer nanotherapeutics: options and opportunities with estrogen receptors.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas S
    Crit Rev Ther Drug Carrier Syst; 2012; 29(5):421-46. PubMed ID: 22876809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery.
    Rai S; Paliwal R; Vaidya B; Gupta PN; Mahor S; Khatri K; Goyal AK; Rawat A; Vyas SP
    Curr Med Chem; 2007; 14(19):2095-109. PubMed ID: 17691950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.
    Vyas SP; Sihorkar V
    Adv Drug Deliv Rev; 2000 Sep; 43(2-3):101-64. PubMed ID: 10967224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier.
    Vinothini K; Rajendran NK; Ramu A; Elumalai N; Rajan M
    Biomed Pharmacother; 2019 Feb; 110():906-917. PubMed ID: 30572195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
    Azim HA; Piccart MJ
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1255-63. PubMed ID: 20735311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting in the estrogen receptor hormonal pathway.
    Katzenellenbogen BS; Frasor J
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer.
    Chauhan K; Hernandez-Meza JM; Rodríguez-Hernández AG; Juarez-Moreno K; Sengar P; Vazquez-Duhalt R
    J Nanobiotechnology; 2018 Feb; 16(1):17. PubMed ID: 29463260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin encapsulated nanocarriers for targeted delivery to estrogen responsive breast cancer.
    Rai S; Paliwal R; Vyas SP
    J Biomed Nanotechnol; 2011 Feb; 7(1):121-2. PubMed ID: 21485833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex hormone receptors in breast cancer.
    D'Abreo N; Hindenburg AA
    Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer treatment and sulfotransferase.
    Ji XW; Zhou TY; Lu Y; Wei MJ; Lu W; Cho WC
    Expert Opin Ther Targets; 2015 Jun; 19(6):821-34. PubMed ID: 25677121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
    Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
    Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
    Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
    Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
    Mittal R; Chaudhry N; Pathania S; Mukherjee TK
    Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
    Szostakowska M; Trębińska-Stryjewska A; Grzybowska EA; Fabisiewicz A
    Breast Cancer Res Treat; 2019 Feb; 173(3):489-497. PubMed ID: 30382472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.
    Hanstein B; Djahansouzi S; Dall P; Beckmann MW; Bender HG
    Eur J Endocrinol; 2004 Mar; 150(3):243-55. PubMed ID: 15012607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of albumin nanoparticles for breast cancer: A review.
    Kunde SS; Wairkar S
    Colloids Surf B Biointerfaces; 2022 May; 213():112422. PubMed ID: 35231688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.